The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling

Cancer

Volumn 82, Issue 12, 1998, Pages 2373-2381

  Shen, Kuo Liang ^a   Harn, Horng Jyh ^a   Ho, Li Ing ^b   Yu, Cheng Ping ^a   Chiu, Shao Chih ^a   Lee, Wei Hwa ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Bcl 2; Breast carcinoma; Estrogen receptor; Infiltrative ductal carcinoma; Intraductal carcinoma (ductal carcinoma in situ); MIB 1; p53; Progesterone receptor; TUNEL

Indexed keywords

DIGOXIGENIN; DNA FRAGMENT; DNA NUCLEOTIDYLEXOTRANSFERASE; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ANTIBODY LABELING; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; CELL SURVIVAL; DEOXYURACIL NUCLEOTIDES; DIGOXIGENIN; DNA FRAGMENTATION; DNA NUCLEOTIDYLEXOTRANSFERASE; DNA, NEOPLASM; FEMALE; GENES, BCL-2; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032526164     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980615)82:12<2373::AID-CNCR11>3.0.CO;2-M     Document Type: Article

References (24)

1. Marshall E. Search for a killer: focus shifts from fat to hormones. Science 1993;258:618-21.
2. Devilee P, Cornellisse C. Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1994;1198:113-30.
3. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer 1990;66: 1326-35.
4. Wyllie AH, Kerr JRR, Currie AR, et al. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
5. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
6. Reed JC. bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
7. Sabourin JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P, et al. bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 1994;59:1-6.
8. Gee JMW, Robertson JFR, Ellis IO, Willsher P, McClelland R, Hoyle HB, et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994;59:619-28.
9. McCormick D, Chong H, Hobbs C, Datta C, et al. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-I. Histopathology 1993; 22:355-60.
10. Gerdes J, Lemke H, Wacker HH, Schwa U, Stein H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Immunology 1984;133:1710-5.
11. Shi SR, Key ME, Kalra KL, et al. Antigen retrieval in formalin-fixed paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39:741-8.
12. Lane DP. p53: the guardian of the genome. Nature 1992;358: 15-6.
13. Bonder SM, Minna JD, Jensen SM, et al. Expression of mutant p53 protein in lung cancer correlates with the class of p53 mutation. Oncogene 1992;7:743-9.
14. Cummings MC, Winterford CM, Walker NI, et al. Apoptosis. Am J Surg Pathol 1997;21:88-101.
15. Peng H-Q, Hogg D, Malkin D, et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1995;53:3574-8.
16. Soini Y, Paakka P. Extent of apoptosis in relation to p53 and bcl-2 expression in germ cell tumors. Hum Pathol 1996;27: 1221-6.
17. Reed JC. bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
18. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
19. Gisbertz IAM, Schouten HC, Bot FJ, Arends JW, et al. Proliferation and apoptosis in primary gastric B-cell non-Hodgkin's lymphoma. Histopathology 1997;30:152-9.
20. Pezzella F, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology 1995;26:89-93.
21. Vaux DL, Gory S, Adams JM, et al. Bcl-2 gene promoters haemopoeitic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-2.
22. Dada MA, Chetty R, Biddolph SC, Schneider JW, Gatter KC, et al. The immunoexpression of bcl-2 and p53 in Kaposi's sarcoma. Histopathology 1996;29:159-63.
23. Harn HJ, Ho LI, Liu CA, Liu GC, Lin FG, Lin JJ, et al. Down-regulation of bcl-2 by p53 in nasopharyngeal carcinoma and lack of detection of its specific t(14;18) chromosomal translocation in fixed tissues. Histopathology 1996;28: 317-23.
24. Ramsey JA, From L, Iscoe NA, Kahn HJ, et al. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous malignant melanoma. J Invest Dermatol 1995;105:22-6.